Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

15 juin 2020 08h01 HE | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I Data and Upcoming Trial Design for SLS-002

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders...
28 mai 2020 07h01 HE | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease

NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
19 mai 2020 09h01 HE | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression

NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
18 mai 2020 08h01 HE | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference

NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
15 mai 2020 10h30 HE | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors

NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
15 mai 2020 07h30 HE | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
12 mai 2020 08h01 HE | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
04 mai 2020 08h01 HE | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)

NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
30 avr. 2020 13h31 HE | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
08 avr. 2020 09h01 HE | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Developments

NEW YORK, April 08, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...

Page suivante